A5013032100- Cancer Immunotherapy and Biomarkers
- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Occupational and environmental lung diseases
- Cancer Genomics and Diagnostics
- Cancer Cells and Metastasis
- Metastasis and carcinoma case studies
- Colorectal Cancer Treatments and Studies
- Lymphoma Diagnosis and Treatment
- Uterine Myomas and Treatments
- Colorectal and Anal Carcinomas
- Intraperitoneal and Appendiceal Malignancies
- HER2/EGFR in Cancer Research
- Sarcoma Diagnosis and Treatment
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Chemokine receptors and signaling
- Endometrial and Cervical Cancer Treatments
- Neuroblastoma Research and Treatments
- Advanced Breast Cancer Therapies
- Peptidase Inhibition and Analysis
- Breast Cancer Treatment Studies
- Pleural and Pulmonary Diseases
- Cancer Treatment and Pharmacology
- Cancer Research and Treatments
- Radiomics and Machine Learning in Medical Imaging
National Cancer Center
2023-2024
Tokyo Metropolitan Komagome Hospital
2018-2024
National Cancer Center Hospital East
2022-2024
Tokyo National Hospital
2021
Higashihiroshima Medical Center
2014
Hiroshima University
2014
Background Based on several phase III studies, immune checkpoint inhibitors (ICIs) are essential and promising drugs for the treatment of non‐small cell lung cancer (NSCLC). However, in patients previously treated with ICI, efficacy safety rechallenging same or another type ICI inhibitor remain unclear. Moreover, clinical data about switching administration anti‐programmed death‐1 (PD‐1) antibodies (e.g. nivolumab, pembrolizumab) death‐ligand 1 (PD‐L1) atezolizumab) as rechallenge limited....
ABSTRACT Despite the importance of genetic testing for risk assessment and treatment in breast cancer, prognostic impact germline pathogenic variants (PVs), especially Asian populations, is unclear. We assessed PVs patients with early‐stage cancer. This study included 7278 Japanese multihospital registry patients. ATM , BRCA1 BRCA2 CDH1 CHEK2 NBN NF1 PALB2 PTEN STK11 TP53 were evaluated. PV non‐PV carriers matched by age, histology, stage. Associations between survival assessed. The primary...
Abstract Background: Ovarian clear cell carcinoma (OCCC) is a rare subtype of ovarian cancer, with higher incidence in East Asia compared to Western countries and tendency affect younger individuals. OCCC has poor prognosis due its low sensitivity chemotherapy, presenting significant unmet medical need. However, therapeutic development been limited rarity. Recently, advancements antibody-drug conjugates (ADCs) targeting Trophoblastic cell-surface marker (TROP2) have shown promise, but the...
Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, therapy docetaxel (Doc) ramucirumab (Ram) was considered one standard treatments advanced or relapsed NSCLC patients. However, little is known about therapeutic responders this among previously treated present study, we aimed identify predictive...
The baseline tumor size (BTS) is a prognostic factor for patients with non-small cell lung cancer (NSCLC) who received immune checkpoint inhibitor monotherapy (ICI-mono). However, this relationship not yet known in treated ICI combination chemotherapy (ICI-chemo).
Abstract Background HER2-low populations constitute a heterogeneous group, and the cytotoxic anticancer agent efficacy based on HER2 status remains unclear. This study evaluated clinicopathological features outcomes of patients with advanced breast cancer showing expression treated eribulin or capecitabine, two treatment options after anthracycline taxane treatment. Methods We retrospectively who were capecitabine between 2011 2015. was according to ASCO/CAP guidelines. Results No...
Abstract Introduction: Antibody-drug conjugates (ADCs) targeting trophoblast cell surface antigen 2 (TROP2), such as sacituzumab-govitecan and datopotamab-deruxtecan, have recently been developed. A preclinical study has reported the efficacy of anti-human epidermal growth factor receptor (HER2) TROP2 bispecific ADCs in treating HER2 co-expressing tumors, including HER2-low tumors various solid (Chengzhang Shang et al: AACR 2023). In this study, we aimed to evaluate expression by...
Mesothelin (MSLN) is a cell-surface glycoprotein found in various solid tumours. Cancer therapies targeting MSLN have been developed recent years; however, the available information on expression cervical cancer limited. This study aimed to evaluate histological types of and examine its relationship with prognosis.This retrospective included patients who underwent primary surgery between January 2000 December 2020 at our institution. was evaluated by immunohistochemistry using clone SP74...
Folate receptor α (FRα) is a membrane protein expressed in various solid tumors but has limited expression normal cells. Therefore, FRα an attractive target for cancer treatment. This study aimed to investigate the relationship between and clinicopathological characteristics survivals of cervical cancer.This retrospective included patients with who underwent primary surgery 2000 2020 at our institution. Immunohistochemical staining was performed using anti-folate-binding protein/FBP...
Abstract Background Standard treatment for malignant peritoneal mesothelioma has not been established, and systemic chemotherapy is administered according to pleural mesothelioma. We previously reported the efficacy of cisplatin plus pemetrexed as first-line chemotherapy; however, second-line remains unknown. Methods retrospectively evaluated patients with who started platinum between March 2007 February 2019 at National Cancer Center Hospital. Patients received after failure were...
Abstract Background Nivolumab has shown promising results against non‐small‐cell lung cancer (NSCLC). However, its efficacy to treat central nervous system (CNS) metastases, specifically among programmed cell death 1 ligand (PD‐L1)‐negative patients, remains unclear. Case A 66‐year‐old woman was diagnosed with adenocarcinoma stage II and underwent a left lower lobectomy. The histopathological evaluation revealed IVA pleural dissemination. patient did not harbor an epidermal growth factor...
<h3>Introduction/Background</h3> Mesothelin (MSLN) is a membrane glycoprotein which highly expressed in many cancers. However, MSLN expression and its prognostic impact patients with gynecologic carcinosarcoma (GCS) remain unknown. We evaluated GCS investigated associations clinicopathological characteristics prognosis uterine (UCS) patients. Additionally, we the correlation between HER2, one of promising treatment strategies for GCS. <h3>Methodology</h3> examined cohort who underwent...
Folate receptor α (FRα) is a cell-surface protein and an attractive target for cancer treatment. We investigated the association between FRα expression tumor immune microenvironment in patients with cervical cancer. examined whole sections of 123 cancer: 67 56 squamous cell carcinoma (SCC) non-SCC, respectively. was assessed using immunohistochemical staining anti-FRα monoclonal antibody clone 26B3. Programmed death-ligand 1 (PD-L1) combined positive score (CPS). The intratumoral CD3 CD8...